• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • EA Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • EA Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Stay Updated
  • We’re hiring!

Diana Shineman, Director for Scientific Affairs, Alzheimer’s Drug Discovery Foundation

  • Focus Area: Scientific Research
  • Content Type: Conversations

Table of Contents

    Published: June 08, 2015

    The Open Philanthropy Project spoke with Dr. Shineman of the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its investigation into Alzheimer’s disease. Conversation topics included the ADDF’s research priorities, challenges and opportunities in the Alzheimer’s disease funding space, and the importance of biomarker development, as well as a number of other issues facing the field.

    Read more

    Related Items

    • Scientific Research

      STAT: For an antiviral researcher, Covid brings a flood of attention — and opportunity

      At the heart of the effort to develop these therapies are scientists like Glenn. For them, Covid is a chance to prove that they can make a difference...

      Read more
    • Scientific Research

      PBS News Hour: In her bid to end TB Mireille Kamariza is shattering stereotypes about scientists

      Mireille Kamariza, CEO of OliLux Biosciences — which recently received an investment from Open Philanthropy — is working on a potential breakthrough diagnostic tool to fight tuberculosis.

      Read more
    • Scientific Research

      The New York Times: The Future of Virus Tracking Can Be Found on This College Campus

      In her role at the Broad Institute, Open Philanthropy grantee Pardis Sabeti worked with Colorado Mesa University to develop a system for pandemic management, versions of which may...

      Read more
    Back to Research & Updates
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    Mailing Address
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    Sign Up to Follow Our Work

    Join Our Mailing List

    © Open Philanthropy 2022